Third expansion of idexx's catalyst platform in under a year delivers critical insights to veterinarians evaluating canine patients for endocrine disorders

The catalyst ® cortisol test provides veterinarians with real-time critical insights when evaluating dogs for addison's disease and cushing's syndrome westbrook, maine , june 5, 2025 /prnewswire/ -- idexx laboratories, inc. (nasdaq: idxx), a global leader in pet healthcare innovation, today announced the launch of the catalyst® cortisol test, which measures real-time quantitative cortisol concentrations to support the diagnosis of addison's disease and diagnosis and management of cushing's syndrome in dogs. idexx's catalyst cortisol test is the third menu expansion in under a year for the catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care.
IDXX Ratings Summary
IDXX Quant Ranking